CAJ | 학술논문

背景:黄精是一种传统的抗衰老中药,其有效成分黄精多糖具有降低血糖和糖化血红蛋白的作用.目的:采用反转录聚合酶链反应测定黄精多糖对蛋白非酶糖基化的关键物质一糖基化终产物受体mRNA表达的调节作用,为开发有效的蛋白非酶糖基化抑制剂和防治糖尿病及其并发症提供实验依据.设计:随机对照动物实验.单位:中南大学湘雅二医院老年病科,中南大学湘雅医学院附属海口医院心内科.材料:实验于2004-03/2004-06在中南大学湘雅二医院实验动物室完成.选用清洁级BALB/C小鼠30只,随机分为正常对照组、模型对照组、黄精多糖治疗组,10只/组.方法:模型对照组、黄精多糖治疗组腹腔注射链脲佐菌素建立糖尿病模型,血糖≥8.0 mmoL/L为造模成功.黄精多糖治疗组予以2 mL/(kg·d)的黄精多糖,正常对照组、模型对照组予以注射用水0.5 mL,1次/d灌胃给药,连续12周.给药完毕后断头处死小鼠,采用反转录-聚合酶链反应法测定各组实验动物心脏、肾组织糖基化终产物mRNA的表达.主要观察指标:①造模12周后各组小鼠大体情况观察.②造模前后各组小鼠血糖的变化.③各组小鼠心脏、肾组织糖基化终产物受体mRNA凝胶电泳图谱.④各组小鼠心脏、肾组织糖基化终产物受体的半定量测定.结果:实验选用30只小鼠,全部进入结果分析.①造模12周后各组小鼠大体情况观察:正常对照组体质量增加,活动自如;模型对照组出现消瘦、多尿、精神萎靡不振、反应迟钝等情况;黄精多糖治疗组多尿症状较轻,反应动作较模型对照组灵敏.②造模前后各组小鼠血糖的变化:正常对照组和模型对照组造模前后血糖基本相似(P＞0.05),黄精多糖治疗组造模12周后血糖显著降低[(10.05±1.16),(7.18±0.84)mmoL/L,P＜0.05].③各组小鼠心脏、肾组织糖基化终产物受体mRNA凝胶电泳图谱:模型对照组小鼠心、肾组织糖基化终产物受体mRNA的表达较正常对照组增高,而黄精多糖治疗组的表达较模型对照组明显降低.④各组小鼠心脏、肾组织糖基化终产物受体的半定量测定:模型对照组心、肾组织糖基化终产物受体/β-actin相对值显著高于正常对照组(P＜0.01);而黄精多糖治疗组其相对值较模型对照组显著降低(0.760±0.121,0.998±0.202;0.609±0.146,0.765±0.113;P均＜0.05).结论:黄精多糖除可降低血糖外,还可显著下调糖尿病鼠心、肾组织糖基化终产物受体mRNA的高表达,进而抑制糖基化终产物的结合位点及与其受体结合后的一系列细胞生物反应,保护高血糖时受损的靶器官和组织. 揹景:黃精是一種傳統的抗衰老中藥,其有效成分黃精多糖具有降低血糖和糖化血紅蛋白的作用.目的:採用反轉錄聚閤酶鏈反應測定黃精多糖對蛋白非酶糖基化的關鍵物質一糖基化終產物受體mRNA錶達的調節作用,為開髮有效的蛋白非酶糖基化抑製劑和防治糖尿病及其併髮癥提供實驗依據.設計:隨機對照動物實驗.單位:中南大學湘雅二醫院老年病科,中南大學湘雅醫學院附屬海口醫院心內科.材料:實驗于2004-03/2004-06在中南大學湘雅二醫院實驗動物室完成.選用清潔級BALB/C小鼠30隻,隨機分為正常對照組、模型對照組、黃精多糖治療組,10隻/組.方法:模型對照組、黃精多糖治療組腹腔註射鏈脲佐菌素建立糖尿病模型,血糖≥8.0 mmoL/L為造模成功.黃精多糖治療組予以2 mL/(kg·d)的黃精多糖,正常對照組、模型對照組予以註射用水0.5 mL,1次/d灌胃給藥,連續12週.給藥完畢後斷頭處死小鼠,採用反轉錄-聚閤酶鏈反應法測定各組實驗動物心髒、腎組織糖基化終產物mRNA的錶達.主要觀察指標:①造模12週後各組小鼠大體情況觀察.②造模前後各組小鼠血糖的變化.③各組小鼠心髒、腎組織糖基化終產物受體mRNA凝膠電泳圖譜.④各組小鼠心髒、腎組織糖基化終產物受體的半定量測定.結果:實驗選用30隻小鼠,全部進入結果分析.①造模12週後各組小鼠大體情況觀察:正常對照組體質量增加,活動自如;模型對照組齣現消瘦、多尿、精神萎靡不振、反應遲鈍等情況;黃精多糖治療組多尿癥狀較輕,反應動作較模型對照組靈敏.②造模前後各組小鼠血糖的變化:正常對照組和模型對照組造模前後血糖基本相似(P＞0.05),黃精多糖治療組造模12週後血糖顯著降低[(10.05±1.16),(7.18±0.84)mmoL/L,P＜0.05].③各組小鼠心髒、腎組織糖基化終產物受體mRNA凝膠電泳圖譜:模型對照組小鼠心、腎組織糖基化終產物受體mRNA的錶達較正常對照組增高,而黃精多糖治療組的錶達較模型對照組明顯降低.④各組小鼠心髒、腎組織糖基化終產物受體的半定量測定:模型對照組心、腎組織糖基化終產物受體/β-actin相對值顯著高于正常對照組(P＜0.01);而黃精多糖治療組其相對值較模型對照組顯著降低(0.760±0.121,0.998±0.202;0.609±0.146,0.765±0.113;P均＜0.05).結論:黃精多糖除可降低血糖外,還可顯著下調糖尿病鼠心、腎組織糖基化終產物受體mRNA的高錶達,進而抑製糖基化終產物的結閤位點及與其受體結閤後的一繫列細胞生物反應,保護高血糖時受損的靶器官和組織.
배경:황정시일충전통적항쇠로중약,기유효성분황정다당구유강저혈당화당화혈홍단백적작용.목적:채용반전록취합매련반응측정황정다당대단백비매당기화적관건물질일당기화종산물수체mRNA표체적조절작용,위개발유효적단백비매당기화억제제화방치당뇨병급기병발증제공실험의거.설계:수궤대조동물실험.단위:중남대학상아이의원노년병과,중남대학상아의학원부속해구의원심내과.재료:실험우2004-03/2004-06재중남대학상아이의원실험동물실완성.선용청길급BALB/C소서30지,수궤분위정상대조조、모형대조조、황정다당치료조,10지/조.방법:모형대조조、황정다당치료조복강주사련뇨좌균소건립당뇨병모형,혈당≥8.0 mmoL/L위조모성공.황정다당치료조여이2 mL/(kg·d)적황정다당,정상대조조、모형대조조여이주사용수0.5 mL,1차/d관위급약,련속12주.급약완필후단두처사소서,채용반전록-취합매련반응법측정각조실험동물심장、신조직당기화종산물mRNA적표체.주요관찰지표:①조모12주후각조소서대체정황관찰.②조모전후각조소서혈당적변화.③각조소서심장、신조직당기화종산물수체mRNA응효전영도보.④각조소서심장、신조직당기화종산물수체적반정량측정.결과:실험선용30지소서,전부진입결과분석.①조모12주후각조소서대체정황관찰:정상대조조체질량증가,활동자여;모형대조조출현소수、다뇨、정신위미불진、반응지둔등정황;황정다당치료조다뇨증상교경,반응동작교모형대조조령민.②조모전후각조소서혈당적변화:정상대조조화모형대조조조모전후혈당기본상사(P＞0.05),황정다당치료조조모12주후혈당현저강저[(10.05±1.16),(7.18±0.84)mmoL/L,P＜0.05].③각조소서심장、신조직당기화종산물수체mRNA응효전영도보:모형대조조소서심、신조직당기화종산물수체mRNA적표체교정상대조조증고,이황정다당치료조적표체교모형대조조명현강저.④각조소서심장、신조직당기화종산물수체적반정량측정:모형대조조심、신조직당기화종산물수체/β-actin상대치현저고우정상대조조(P＜0.01);이황정다당치료조기상대치교모형대조조현저강저(0.760±0.121,0.998±0.202;0.609±0.146,0.765±0.113;P균＜0.05).결론:황정다당제가강저혈당외,환가현저하조당뇨병서심、신조직당기화종산물수체mRNA적고표체,진이억제당기화종산물적결합위점급여기수체결합후적일계렬세포생물반응,보호고혈당시수손적파기관화조직.
BACKGROUND: Siberian solomonseal rhizome is a sort of Chinese traditional medicine for anti-senilism. The effective component, poly gonati polysaccharide, has the effects of reducing blood glucose and glycosylhemoglobin.OBJECTIVE: To assay regulative effect of polygonati polysaccharide on expression of the key substance of non-enzymic glycosylation of proteinsglycosylated end-product receptor mRNA by reverse transcriptase polymerase chain reaction, so as to develop effective inhibitor for non-enzymic glycosylation of proteins and provide experimental evidences for preventing diabetes and its complications.DESIGN: Randomized control animal trial SETTING: Department of Geriatrics, the Second Xiangya Hospital, Central South University; Department of Cardiology, Haikou Hospital Affiliated to Xiangya Medical College, Central South University.MATERIALS: The experiment was completed in Animal Room of Second Xiangya Hospital of Central South University form March to June 2004. A total of 30 BALB/C mice of clean grade were selected and randomly divided into normal control group, model control group and polygonati polysaccharide group, with 10 in each group.METHODS: Diabetic models were established by intraperitoneal injection with streptozotocin to mice in model control group and polygonati polysaccharide group. Model establishment would be regard as successful if blood glucose of mouse was 8.0 mmoL/L or above. Mice in polygonati polysaccharide group were treated with polygonati polysaccharide (2 mL/kg per day), while mice in normal control group and model control group were treated with injection of 0.5 mL water once a day for 12 consecutive weeks.After medicine had been given to the mice, they were put to death by decapitation. Reverse transcriptase polymerase chain reaction was used to assay expression of glycosylated end-product receptor mRNA in cardiac and renal tissues of experimental animals.MAIN OUTCOME MEASURES: ① Observation of general situation of mice in each group 12 weeks later after model establishment. ② Change of blood glucose of mice in each group before and after model establishment.③ Gel electrophoretic maps of glycosylated end-product receptor mRNA in cardiac and renal tissue of mice in each group. ④ Semi-quantitative assay of glycosylated end-product receptor in cardiac and renal tissue of mice in each groupRESULTS: All the 30 mice entered the results analysis. ① Observation of general situation of mice in each group 12 weeks later after model establishment: mice in normal control group gained weight and moved freely; mice in model control group manifested the symptoms of losing weight, polyuria, listlessness, lags in response etc.; mice in polygonati polysaccharide group manifested milder symptom of polyuria and more sensitive in responses as compared with model control group.② Changes of blood glucose of mice in each group before and after model establishment: blood glucose levels were similar between normal control group and model control group before and after model establishment (P ＞ 0.05), while blood glucose in polygonati polysaccharide group significantly decreased 12 weeks later after model establishment [(10.05±1.16), (7.18±0.84) mmoL/L, P ＜ 0.05]. ③ Gel electrophoretic maps of glycosylated end-product receptor mRNA in cardiac and renal tissue of mice in each group: Compared with normal control group, the expression of glycosylated end-product receptor mRNA increased in cardiac and renal tissue of mice in model control group, while the expression in polygonati polysaccharide group significantly decreased as compared with model control group. ④ Semi-quantitative assay of glycosylated end-product receptor in cardiac and renal tissue of mice in each group: the relative value of glycosylated end-product receptor to β-actin in cardiac and renal tissue of mice in model control group was significantly higher than normal control group (P ＜ 0.01); however, the relative value of polygunati polysaccharide group significantly decreased as compared with model control group (0.760±0.121,0.998±0.202;0.609±0.146;0.765±0.113; P ＜ 0.05).CONCLUSION: Besides reducing blood glucose, polygonati polysaccharide can significantly down regulate high expression of glycosylated endproduct receptor mRNA in cardiac and renal tissue of mice with diabetes, so as to inhibit the combining sites for glycosylated end-products and a series of cytobiological reactions after combined with their receptors, and protect the target organs and tissues from injuring by hyperglycemia.